161 related articles for article (PubMed ID: 10587283)
1. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients.
Carrillo JA; Ramos SI; Herraiz AG; Llerena A; Agundez JA; Berecz R; Duran M; Benítez J
J Clin Psychopharmacol; 1999 Dec; 19(6):494-9. PubMed ID: 10587283
[TBL] [Abstract][Full Text] [Related]
2. The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies.
Daniel WA; Syrek M; Haduch A; Wójcikowski J
Exp Toxicol Pathol; 1999 Jul; 51(4-5):309-14. PubMed ID: 10445388
[TBL] [Abstract][Full Text] [Related]
3. Factors affecting drug concentrations and QT interval during thioridazine therapy.
Thanacoody RH; Daly AK; Reilly JG; Ferrier IN; Thomas SH
Clin Pharmacol Ther; 2007 Nov; 82(5):555-65. PubMed ID: 17460606
[TBL] [Abstract][Full Text] [Related]
4. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.
Berecz R; de la Rubia A; Dorado P; Fernández-Salguero P; Dahl ML; LLerena A
Eur J Clin Pharmacol; 2003 May; 59(1):45-50. PubMed ID: 12682803
[TBL] [Abstract][Full Text] [Related]
5. Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity.
Llerena A; Berecz R; de la Rubia A; Norberto MJ; Benítez J
Ther Drug Monit; 2000 Aug; 22(4):397-401. PubMed ID: 10942178
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study.
Wetzel H; Anghelescu I; Szegedi A; Wiesner J; Weigmann H; Härter S; Hiemke C
J Clin Psychopharmacol; 1998 Feb; 18(1):2-9. PubMed ID: 9472836
[TBL] [Abstract][Full Text] [Related]
7. Absorption and excretion of thioridazine and mesoridazine in man.
Charalampous KD; Johnson PC; Estevez V
Dis Nerv Syst; 1974 Nov; 35(11):494-6. PubMed ID: 17896456
[TBL] [Abstract][Full Text] [Related]
8. Light-induced racemization: artifacts in the analysis of the diastereoisomeric pairs of thioridazine 5-sulfoxide in the plasma and urine of patients treated with thioridazine.
Eap CB; Souche A; Koeb L; Baumann P
Ther Drug Monit; 1991 Jul; 13(4):356-62. PubMed ID: 1780970
[TBL] [Abstract][Full Text] [Related]
9. Mesoridazine and thioridazine: clinical effects and blood levels in refractory schizophrenics.
Vital-Herne J; Gerbino L; Kay SR; Katz IR; Opler LA
J Clin Psychiatry; 1986 Jul; 47(7):375-9. PubMed ID: 2873133
[TBL] [Abstract][Full Text] [Related]
10. No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients.
Dorado P; Berecz R; Peñas-Lledó EM; de la Rubia A; Llerena A
Eur J Clin Pharmacol; 2007 May; 63(5):527-8. PubMed ID: 17345072
[No Abstract] [Full Text] [Related]
11. Determination of the enantiomers of thioridazine, thioridazine 2-sulfone, and of the isomeric pairs of thioridazine 2-sulfoxide and thioridazine 5-sulfoxide in human plasma.
Eap CB; Koeb L; Powell K; Baumann P
J Chromatogr B Biomed Appl; 1995 Jul; 669(2):271-9. PubMed ID: 7581903
[TBL] [Abstract][Full Text] [Related]
12. Relevance of CYP2D6 -1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients.
Dorado P; Peñas-LLedó EM; de la Rubia A; LLerena A
Pharmacogenomics; 2009 Jul; 10(7):1083-9. PubMed ID: 19604081
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of thioridazine and its metabolites in blood plasma and the brain of rats after acute and chronic treatment.
Daniel WA; Syrek M; Mach A; Wójcikowski J; Boksa J
Pol J Pharmacol; 1997; 49(6):439-52. PubMed ID: 9566048
[TBL] [Abstract][Full Text] [Related]
14. Concentration and distribution of thioridazine and metabolites in schizophrenic post-mortem brain tissue.
Svendsen CN; Hrbek CC; Casendino M; Nichols RD; Bird ED
Psychiatry Res; 1988 Jan; 23(1):1-10. PubMed ID: 3363012
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses.
Salih IS; Thanacoody RH; McKay GA; Thomas SH
Clin Pharmacol Ther; 2007 Nov; 82(5):548-54. PubMed ID: 17410120
[TBL] [Abstract][Full Text] [Related]
16. [Clozapine-resistant schizophrenia related to an increased metabolism and benefit of fluvoxamine: four case reports].
Papetti F; Morel-Pingault V; Buisse V; Maziere L; Banayan M; Thauby S; Besnard T; Darcourt G; Pringuey D
Encephale; 2007 Oct; 33(5):811-8. PubMed ID: 18357853
[TBL] [Abstract][Full Text] [Related]
17. Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial.
Szegedi A; Anghelescu I; Wiesner J; Schlegel S; Weigmann H; Härtter S; Hiemke C; Wetzel H
Pharmacopsychiatry; 1999 Jul; 32(4):148-53. PubMed ID: 10505485
[TBL] [Abstract][Full Text] [Related]
18. Dose-dependent effect of the CYP2D6 genotype on the steady-state fluvoxamine concentration.
Watanabe J; Suzuki Y; Fukui N; Sugai T; Ono S; Inoue Y; Someya T
Ther Drug Monit; 2008 Dec; 30(6):705-8. PubMed ID: 18978520
[TBL] [Abstract][Full Text] [Related]
19. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects.
Hiemke C; Peled A; Jabarin M; Hadjez J; Weigmann H; Härtter S; Modai I; Ritsner M; Silver H
J Clin Psychopharmacol; 2002 Oct; 22(5):502-6. PubMed ID: 12352274
[TBL] [Abstract][Full Text] [Related]
20. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients.
Lu ML; Lane HY; Chen KP; Jann MW; Su MH; Chang WH
J Clin Psychiatry; 2000 Aug; 61(8):594-9. PubMed ID: 10982203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
